FDA Grants Second Approval for Gilead’s Trodelvy

FDA Grants Second Approval for Gilead’s Trodelvy

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Trodelvy, a drug therapy for patients with locally advanced or metastatic urothelial cancer (mUC), an aggressive disease with a survival rate of 5.5%. Previously, Trodelvy was granted...